Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR5 | P51681 | 13/20 | 0.86 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.44 |
| ▸ | OPRL1 | P41146 | 3/20 | 0.44 |
| ▸ | HTR1A | P08908 | 1/20 | 0.42 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.42 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.42 |
| ▸ | CACNA1F | O60840 | 1/20 | 0.41 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.41 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.41 |
| ▸ | DRD2 | P14416 | 1/20 | 0.41 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.41 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.41 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.41 |
| ▸ | HRH1 | P35367 | 1/20 | 0.41 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.41 |
| ▸ | DRD3 | P35462 | 1/20 | 0.41 |
| ▸ | CACNA1D | Q01668 | 1/20 | 0.41 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.41 |
| ▸ | CACNA1S | Q13698 | 1/20 | 0.41 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13544014 | 0.96 | CCR5 (0.86) | CCR5OPRM1OPRL1HTR1AOPRD1 | |
| SCHEMBL4683214 | 0.93 | CCR5 (1.00) | CCR5OPRM1OPRL1OPRD1OPRK1 | |
| SCHEMBL13544011 | 0.89 | CCR5 (1.00) | CCR5OPRM1OPRL1OPRD1OPRK1 | |
| SCHEMBL4679294 | 0.84 | CCR5 (0.68) | CCR5OPRM1OPRL1 | |
| SCHEMBL13544013 | 0.83 | CCR5 (0.66) | CCR5OPRM1OPRL1 | |
| SCHEMBL4685629 | 0.82 | CCR5 (0.64) | CCR5OPRM1OPRL1 | |
| SCHEMBL4682434 | 0.81 | CCR5 (0.85) | CCR5OPRM1OPRL1HTR1A | |
| SCHEMBL6170250 | 0.81 | CCR5 (0.63) | CCR5OPRM1OPRL1HTR1AOPRK1 | |
| SCHEMBL5511844 | 0.80 | CCR5 (0.85) | CCR5HTR1AOPRK1SLC6A3 | |
| SCHEMBL13544010 | 0.80 | CCR5 (0.78) | CCR5OPRM1OPRL1HTR1AOPRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060058284-A1 | Pyrrolidine and azetidine compounds as ccr5 antagonists | SMITHKLINE BEECHAM CORPORATION | 2006-03-16 | — | — | US | claimed |
| EP-1569933-A1 | PYRROLIDINE AND AZETIDINE COMPOUNDS AS CCR5 ANTAGONISTS | SmithKline Beecham Corporation (US) | 2005-09-07 | — | — | EP | claimed |
| WO-2004055016-A1 | PYRROLIDINE AND AZETIDINE COMPOUNDS AS CCR5 ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 2004-07-01 | — | — | WO | claimed |
| EP-1569933-B1 | PYRROLIDINE AND AZETIDINE COMPOUNDS AS CCR5 ANTAGONISTS | SMITHKLINE BEECHAM CORP (US) | 2008-07-23 | — | — | EP | disclosed |
| US-7271172-B2 | Pyrrolidine and azetidine compounds as CCR5 antagonists | SMITHKLINE BEECHAM CORPORATION (US) | 2007-09-18 | — | — | US | disclosed |
| US-7271172-B2 | Pyrrolidine and azetidine compounds as CCR5 antagonists | SMITHKLINE BEECHAM CORPORATION (US) | 2007-09-18 | — | — | US | disclosed |
| US-20060058284-A1 | Pyrrolidine and azetidine compounds as ccr5 antagonists | SMITHKLINE BEECHAM CORPORATION | 2006-03-16 | — | — | US | disclosed |
| EP-1569933-A1 | PYRROLIDINE AND AZETIDINE COMPOUNDS AS CCR5 ANTAGONISTS | SmithKline Beecham Corporation (US) | 2005-09-07 | — | — | EP | disclosed |
| WO-2004055016-A1 | PYRROLIDINE AND AZETIDINE COMPOUNDS AS CCR5 ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 2004-07-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060058284-A1 | Pyrrolidine and azetidine compounds as ccr5 antagonists | CCR5, CCL5, CXCR1 | CCR5 1/4885OPRM1 153/4885OPRL1 196/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.